Navigation Links
Accera, Inc. Names William T. Poncy Vice President of Commercial Development
Date:10/10/2007

BROOMFIELD, Colo., Oct. 10 /PRNewswire/ -- Accera Inc., a privately held biotechnology company focused on developing novel drugs for neurodegenerative diseases, today announced that it has appointed William T. Poncy, M.B.A., as vice president of commercial development. Mr. Poncy will direct the commercial launch of Ketasyn (AC-1202) as a medical food product in the U.S. for the treatment of Alzheimer's disease.

"Given his strong track record in all aspects pharmaceutical commercialization, we are thrilled to welcome Bill to our management team," commented Steve Orndorff, Ph.D., president and CEO. "We are confident that his strong track record combined with Ketasyn's excellent safety and efficacy will allow Accera to make a competitive entry into the multi billion-dollar Alzheimer's market."

Additionally, Mr. Poncy will be responsible for developing Accera's neurodegenerative disease franchise for ethical drugs now in development for Parkinson's disease, Huntington's disease, and age-associated memory impairment.

With more than 25 years of experience in the pharmaceutical industry, Mr. Poncy most recently served as vice president of sales and marketing at Myogen, Inc. (now Gilead Sciences), where he built the commercial organization and launched a pulmonary anti-hypertension franchise. Previously he was the North American vice president of sales and marketing for Pharmion Corp., where he developed an oncology commercial organization. He has also held positions in sales, managed care, trade, marketing and various management roles at DuPont Pharmaceuticals and Berlex Labs.

About Accera, Inc.

Based in Broomfield, CO, Accera, Inc. is a privately held biotechnology company focused on developing novel drugs for neurodegenerative diseases. The company's lead candidate, Ketasyn(TM) (AC-1202), is a first-in-class molecule that earlier this year completed successful Phase II clinical trials for Alzheimer's disease (AD) and age-associated memory impairment (AAMI). Accera plans to self-commercialize Ketasyn as a medical food for the treatment of AD in the US in 2008. A key element of Accera's strategy is work with corporate partners to commercialize Ketasyn in non-U.S. markets, and to develop AC-1202 and other proprietary small molecule compounds in its pipeline for a range of memory and cognition disorders associated with neurological conditions and aging. http://www.accerapharma.com

About Ketasyn(TM)

Brain imaging techniques performed on Alzheimer's patients reveal a dramatically decreased uptake of glucose, the brain's preferred source of energy. Known as neuronal hypometabolism, this condition resembles diabetes in the brain, or Type III diabetes. Ketasyn(TM) (AC-1202) is an orally available, liquid compound that is efficiently converted into ketone bodies, an alternative energy source that the brain can use even when glucose metabolism is impaired. By preserving glucose-deprived neurons, Ketasyn demonstrates neuroprotective and disease modifying potential in a number other neurodegenerative diseases characterized by neuronal hypometabolism. This first-in-class compound is also being evaluated in age-associated memory impairment, Parkinson's disease, and selected orphan drug indications.

About Medical Foods

The Food and Drug Administration defines a medical food as a food to be consumed or administered orally under medical supervision for the dietary management of a disease or condition for which specific nutritional requirements have been scientifically proven. Medical foods are specially formulated and processed to meet these nutritional requirements, which modification of the diet alone cannot satisfy. Medical foods may be prescribed by a physician for a patient actively receiving medical attention for a specific disease or condition, and are subject to the general food and safety labeling requirements of the Federal Food Drug and Cosmetic Act.

For information contact:

Meghan Feeks

Richard Lewis Communications, Inc.

212-827-0020

mfeeks@rlcinc.com


'/>"/>
SOURCE Accera Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Wisconsin IT association names Gee president, CEO
2. Quintessence Biosciences names new president
3. CDW names VP to handle Berbee merger
4. NimbleGen names CFO with capital-raising past
5. Cisco names Berbee a top partner of 2005
6. Cisco names Inacom most innovative partner
7. UW-Madison medical school names new dean
8. GE Healthcare names new CEO
9. Bruker AXS names new leadership
10. Sonic Foundry names new senior vice president
11. MyWeather names new president, marketing officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of ... their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been ... Target to its list of well-respected retailers. This list includes such fine stores ...
(Date:6/23/2016)... SPRING, Md. , June 23, 2016 A ... collected from the crime scene to track the criminal down. ... and the U.S. Food and Drug Administration (FDA) uses DNA ... Sound far-fetched? It,s not. The ... genome sequencing to support investigations of foodborne illnesses. Put as ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
Breaking Biology News(10 mins):